Compared side by side

5-Amino-1MQ vs semaglutide: how they differ

Reviewed How we check the libraryPublished by PepVault

The short answer

Semaglutide is a GLP-1 receptor agonist that reduces appetite and slows stomach emptying; 5-Amino-1MQ is a small molecule (not a peptide) that blocks the NNMT enzyme in fat cells, and in obese mice it cut weight and fat without reducing food intake. Semaglutide is FDA-approved, with about 15% average weight loss at 68 weeks in its main trial, and 5-Amino-1MQ has no human studies. Commonly reported: “food noise” going quiet on semaglutide, and nothing to feel on 5-Amino-1MQ, though some describe easier fat loss alongside a deficit or a GLP-1.

Side by side

Compared5-Amino-1MQSemaglutide
CategoryMetabolic & GLP-1Metabolic & GLP-1
Also known as5-A-1MQ, 5Amino1MQ, 5-Amino-1-methylquinoliniumOzempic, Wegovy
What it isA small molecule (not a peptide) that blocks the NNMT enzyme in fat cells, which raises NAD+ and pushes fat cells toward burning energy.A GLP-1 receptor agonist that mimics a gut hormone your body releases after eating: it reduces appetite and slows stomach emptying.
How it worksNNMT (Nicotinamide N-methyltransferase) inhibitor that blocks NNMT activity in fat cells. In cultured fat cells it raises NAD+ and SAM levels; in obese mice it cut body weight and fat without reducing food intake, and with a reduced-calorie diet lean mass made up a larger share of body weight. No human data.GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves glucose metabolism. FDA-approved for T2DM and obesity. Titrate dose slowly to minimize GI side effects.
Commonly reportedNothing to feel, though some describe easier fat loss alongside a deficit or a GLP-1. There are no human studies, and the mouse work used injections rather than oral doses.The constant background thoughts about food ("food noise") go quiet and portions shrink without effort, with nausea worst in the first days after each dose step. FDA-approved for type 2 diabetes, weight management, heart-risk reduction and MASH, with about 15% average weight loss at 68 weeks in its main trial.
Studied rangeResearch range: 50–100 mg. Studied in research — not a recommendation.FDA label: 0.25–2.4 mg, starting dose 0.25 mg.
How oftenDailyWeekly SubQ
Half-lifeUnknown~1 week (FDA label)
RouteOralSubQ injection
Typical runVery limited data. Some run 8–12 weeks then cycle off. Preclinical compound — approach conservatively.FDA-approved for ongoing use. Community uses indefinitely or until goal weight reached, then tapers.
EvidenceEmerging: primarily preclinical / limited human dataEstablished: clinical trials or FDA-approved use exists
Common side effectsLimited human data, generally well tolerated in early researchNausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis risk

Typical run: Community practice — opinions vary. Not a clinical recommendation.

A smiling man in a grey t-shirt in his living room, holding his phone

Model. Individual results vary.

PepVault for iPhone

Taking 5-Amino-1MQ or semaglutide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Week by week

Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.

5-Amino-1MQ

  • Day 1–28 Quiet compound, slow signal
  • Day 28–84 Recomp in a deficit
  • Day 84–168 Cycle decision point

Every card for 5-Amino-1MQ, with its sources

Semaglutide

  • Day 1–28 · 0.25 mg Gut is adapting
  • Day 29–56 · 0.5 mg Appetite shifts are real now
  • Day 57–112 · 1 mg Clinically useful weight loss kicks in
  • Day 113–140 · 1.7 mg Max submaximal step
  • Day 141–364 · 2.4 mg Full dose — the working dose
  • Day 365+ Plateau territory — new baseline

Every card for semaglutide, with its sources

Together or one or the other

5-Amino-1MQ and semaglutide are a common stack: 5-Amino-1MQ lists semaglutide among its common stacks.

Community · 5-Amino-1MQ

Layered onto a GLP-1 cut

Common community pattern: 5-Amino-1MQ layered onto an ongoing GLP-1 protocol. The GLP-1 drives the calorie deficit while 5-Amino-1MQ helps protect lean mass from the fat-cell side (a mouse finding). Commonly reported: some find recomposition a bit easier; others notice no change.

Questions people ask

How long do 5-Amino-1MQ and semaglutide last?

The half-life of 5-Amino-1MQ is unknown. The half-life of semaglutide is ~1 week (FDA label).

How often are 5-Amino-1MQ and semaglutide taken?

5-Amino-1MQ: daily. Route: Oral. Semaglutide: weekly SubQ. Route: SubQ injection.

How are 5-Amino-1MQ and semaglutide dosed in research?

The research range for 5-Amino-1MQ is 50–100 mg. Studied in research — not a recommendation. The FDA label range for semaglutide is 0.25–2.4 mg, with a 0.25 mg starting dose.

What are the common side effects of 5-Amino-1MQ and semaglutide?

For 5-Amino-1MQ, the library lists: limited human data, generally well tolerated in early research. For semaglutide: nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis risk.

Are 5-Amino-1MQ and semaglutide taken together?

5-Amino-1MQ and semaglutide are a common stack: 5-Amino-1MQ lists semaglutide among its common stacks. Common community pattern: 5-Amino-1MQ layered onto an ongoing GLP-1 protocol. The GLP-1 drives the calorie deficit while 5-Amino-1MQ helps protect lean mass from the fat-cell side (a mouse finding). Commonly reported: some find recomposition a bit easier; others notice no change.

Each one in full

Track it in the app

PepVault for iPhone

Taking 5-Amino-1MQ or semaglutide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo